Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Merus Stock Is Flying Higher Today

By Cory Renauer – Oct 7, 2021 at 10:48AM

Key Points

  • Merus presented pre-clinical data for its lead candidate, zenocutuzumab, and MCLA-158 at a scientific conference today.
  • Impressive results among the first seven patients treated with MCLA-158 in a phase 1 clinical trial are pushing the stock higher today.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This biotech's second experimental cancer drug to begin clinical trials produced some encouraging results.

What happened

Shares of Merus (MRUS -1.32%), a clinical-stage biopharmaceutical company, are soaring today in response to positive clinical trial results. Investors impressed with the company's latest presentation pushed the stock 39% higher as of 10:16 a.m. EDT on Thursday.

So what 

Today, Merus presented data from a clinical trial with MCLA-158 in patients with head and neck squamous cell cancer (HNSCC). The company also presented some pre-clinical data from its lead asset, zenocutuzumab, but all eyes were on MCLA-158.

Happy investor in front of an upward sloping chart.

Image source: Getty Images.

Among the first seven patients treated with MCLA-158 who also have at least eight weeks of follow-up observation, none of the targeted tumors got bigger. Three patients even exhibited a partial response.

Now what

MCLA-158 is a bispecific antibody that binds to cancer cells that express too much leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5) and epidermal growth factor receptor (EGFR). In theory, this should arrest tumor growth and recruit immune cells to attack those tumors at the same time.

So far, it looks like MCLA-158's unique approach is working as expected. When it comes to new cancer drug development, though, early looks can be deceiving. Impressive response rates that appear after the first handful of patients almost always become less impressive with time. Before risking money on Merus stock, it's probably a good idea to wait for a little more data.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Stocks Mentioned

Merus Stock Quote
$14.97 (-1.32%) $0.20

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.